Neurocrine Biosciences (NBIX) reported 622.1millioninrevenueforthequarterendedSeptember2024,representingayear−over−yearincreaseof24.71.24 for the same period compares to 0.82ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof604.11 million, representing a surprise of +2.98%. The company delivered an EPS surprise of -15.65%, with the consensus EPS estimate being $1.47.While investors closely watch year-over-year changes in headline numbers -- revenue and ...